Hatch Opposes CMS’ Proposal To Drive Down Prices Of Biosimilars

Senate Finance Committee Chair Orrin Hatch (R-UT) on Thursday (Oct. 22) told CMS acting Administrator Andrew Slavitt he should scrap a proposal to place biosimilars that reference the same brand biologics in single billing codes. CMS might release Friday a regulation that includes the biosimilar proposal, but the agency indicated that it will extend the comment period on that regulation. Putting biosimilars in the same billing codes likely would create price competition that drives down their price. Opponents say that...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.